SciELO - Scientific Electronic Library Online

vol.135 issue11Socioeconomic and educational inequities as independent predictors for mortality in a developing country: A cohort study in San Francisco, ChileShigella spp Infections In children living In the Metropolitan RegionChile, during summer of 2004-2005 author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand




Related links


Revista médica de Chile

Print version ISSN 0034-9887


GARRIDO, Marcelo et al. Treatment of advanced gastric cancer with oxaliplatin plus 5-fluorouracil/ leucovorin (FOLFOX-4 chemotherapy). Rev. méd. Chile [online]. 2007, vol.135, n.11, pp.1380-1387. ISSN 0034-9887.

Background: Chemotherapy improves survival in advanced gastric cancer. However the most active combinations have a high level of toxicity that limits their use. Aim: To assess the response, toxicity and survival of patients with advanced gastric cancer, treated with oxaliplatin plus 5-fluorouracil/leucovorin (FOLFOX-4 chemotherapy). Material and methods: Patients with stage IVgastric cancer, according to the American Joint Committee on Cancer or with relapsed disease and functional capacity 0-2 of the South West Oncology Group, were included. FOLFOX-4 chemotherapy was used as first or second line treatment. The response to treatment and survival were assessed. Results: Between 2003 and 2006, 29 patients (median age 52.5 years, 69% males) were treated. FOLFOX-4 was given as first line treatment in 65% patients and as second line in 35%. There was a complete response in 4.6%, partial response in 68%, stable disease in 20.6% and progression in 6.8%. Toxicity was observed in 51% of patients, that was hematological and non hematological grade 3/4 in 14%. Median survival was 12.5 months. Conclusions: FOLFOX-4 chemotherapy was active in advanced gastric cancer and had a low level of toxicity

Keywords : Antineoplastic combined chemotherapy protocols; Órgano platinum compounds; Stomach neoplasms.

        · text in Spanish     · Spanish ( pdf )


Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License